Search Results
You are looking at 1 - 3 of 3 items for
- Author: Dirk Vanderschueren x
- Refine by access: All content x
Search for other papers by Filip Callewaert in
Google Scholar
PubMed
Search for other papers by Mieke Sinnesael in
Google Scholar
PubMed
Search for other papers by Evelien Gielen in
Google Scholar
PubMed
Search for other papers by Steven Boonen in
Google Scholar
PubMed
Search for other papers by Dirk Vanderschueren in
Google Scholar
PubMed
Structural gender differences in bone mass – characterized by wider but not thicker bones – are generally attributed to opposing sex steroid actions in men and women. Recent findings have redefined the traditional concept of sex hormones as the main regulators of skeletal sexual dimorphism. GH–IGF1 action is likely to be the most important determinant of sex differences in bone mass. Estrogens limit periosteal bone expansion but stimulate endosteal bone apposition in females, whereas androgens stimulate radial bone expansion in males. Androgens not only act directly on bone through the androgen receptor (AR) but also activate estrogen receptor-α or -β (ERα or ERβ) following aromatization into estrogens. Both the AR and ERα pathways are needed to optimize radial cortical bone expansion, whereas AR signaling alone is the dominant pathway for normal male trabecular bone development. Estrogen/ERα-mediated effects in males may – at least partly – depend on interaction with IGF1. In addition, sex hormones and their receptors have an impact on the mechanical sensitivity of the growing skeleton. AR and ERβ signaling may limit the osteogenic response to loading in males and females respectively, while ERα may stimulate the response of bone to mechanical stimulation in the female skeleton. Overall, current evidence suggests that skeletal sexual dimorphism is not just the end result of differences in sex steroid secretion between the sexes, but depends on gender differences in GH–IGF1 and mechanical sensitivity to loading as well.
Search for other papers by Ferran Jardí in
Google Scholar
PubMed
Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium
Search for other papers by Michaël R Laurent in
Google Scholar
PubMed
Search for other papers by Vanessa Dubois in
Google Scholar
PubMed
Search for other papers by Nari Kim in
Google Scholar
PubMed
Search for other papers by Rougin Khalil in
Google Scholar
PubMed
Search for other papers by Brigitte Decallonne in
Google Scholar
PubMed
Search for other papers by Dirk Vanderschueren in
Google Scholar
PubMed
Search for other papers by Frank Claessens in
Google Scholar
PubMed
Physical inactivity is a pandemic that contributes to several chronic diseases and poses a significant burden on health care systems worldwide. The search for effective strategies to combat sedentary behavior has led to an intensification of the research efforts to unravel the biological substrate controlling activity. A wide body of preclinical evidence makes a strong case for sex steroids regulating physical activity in both genders, albeit the mechanisms implicated remain unclear. The beneficial effects of androgens on muscle as well as on other peripheral functions might play a role in favoring adaptation to exercise. Alternatively or in addition, sex steroids could act on specific brain circuitries to boost physical activity. This review critically discusses the evidence supporting a role for androgens and estrogens stimulating male physical activity, with special emphasis on the possible role of peripheral and/or central mechanisms. Finally, the potential translation of these findings to humans is briefly discussed.
Search for other papers by Johan Svensson in
Google Scholar
PubMed
Search for other papers by Jon Kindblom in
Google Scholar
PubMed
Search for other papers by Ruijin Shao in
Google Scholar
PubMed
Search for other papers by Sofia Movérare-Skrtic in
Google Scholar
PubMed
Search for other papers by Marie K Lagerquist in
Google Scholar
PubMed
Search for other papers by Niklas Andersson in
Google Scholar
PubMed
Search for other papers by Klara Sjögren in
Google Scholar
PubMed
Search for other papers by Katrien Venken in
Google Scholar
PubMed
Search for other papers by Dirk Vanderschueren in
Google Scholar
PubMed
Search for other papers by John-Olov Jansson in
Google Scholar
PubMed
Search for other papers by Olle Isaksson in
Google Scholar
PubMed
Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Both IGF1 and androgens are major enhancers of prostate growth and are implicated in the development of prostate hyperplasia and cancer. The aim of the present study was to investigate whether liver-derived endocrine IGF1 modulates the androgenic response in prostate. Mice with adult, liver-specific inactivation of IGF1 (LI-IGF1−/− mice) displayed an ∼80% reduction in serum IGF1 levels associated with decreased prostate weight compared with control mice (anterior prostate lobe −19%, P<0.05; dorsolateral prostate (DLP) lobe −35%, P<0.01; ventral prostate (VP) lobe −47%, P<0.01). Reduced androgen receptor (Ar) mRNA and protein levels were observed in the VP lobe (−34% and −30% respectively, both P<0.05 versus control mice). Analysis of prostate morphology showed reductions in both the glandular and fibromuscular compartments of the VP and DLP lobes that were proportional to the reductions in the weights of these lobes. Immunohistochemistry revealed reduced intracellular AR immunoreactivity in the VP and DLP lobes. The non-aromatizable androgen dihydrotestosterone increased VP weight to a lesser extent in orchidectomized (ORX) LI-IGF1−/− mice than in ORX controls (−40%, P<0.05 versus control mice). In conclusion, deficiency of liver-derived IGF1 reduces both the glandular and fibromuscular compartments of the prostate, decreases AR expression in prostate, and reduces the stimulatory effect of androgens on VP weight. These findings may explain, at least in part, the well-known clinical association between serum IGF1 levels and conditions with abnormal prostate growth.
